CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use

AIDS

Volumn 27, Issue 6, 2013, Pages 907-918

  Mocroft, Amanda ^a   Phillips, Andrew N ^a   Gatell, Jose ^b   Horban, Andrej ^c   Ledergerber, Bruno ^d   Zilmer, Kai ^e   Jevtovic, Djordje ^f   Maltez, Fernando ^g   Podlekareva, Daria ^h   Lundgren, Jens D ^h,i  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HOSPITAL CLÍNIC   (Spain)

^c SP ZOZ Wojewodzki Szpital Zakazny Centrum Diagnostyki i Terapii AIDS Warszawa   (Poland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e WEST TALLINN CENTRAL HOSPITAL   (Estonia)

^f UNIVERSITY OF BELGRADE   (Serbia)

^g HOSPITAL CURRY CABRAL   (Portugal)

^h UNIVERSITY OF COPENHAGEN   (Denmark)

ⁱ Rigshospitalet   (Denmark)

Author keywords

AIDS; CD4 cell count; Combination antiretroviral therapy; Death; Non AIDS; Viral load

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INDINAVIR; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE; SAQUINAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; ESOPHAGUS CANDIDIASIS; FEMALE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HUMAN; INCIDENCE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VIRAL LOAD;

EID: 84876374276     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835cb766     Document Type: Article

References (35)

1. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents 2012. http://AIDSinfo.nih.gov. [Accessed 19 October 2012].
2. Hughes MD, Daniels MJ, Fischl MA, Kim S, Schooley RT. CD4 cell count as a surrogate endpoint in HIV clinical trials: A metaanalysis of studies of the AIDS Clinical Trials Group. AIDS 1998; 12:1823-1832.
3. Marschner IC, Collier AC, Coombs RW, D'Aquila RT, DeGruttola V, Fischl MA, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998; 177:40-47.
4. O'Brien TR, Blattner WA, Waters D, Eyster E, Hilgartner MW, Cohen AR, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 1996; 276:105-110.
5. Reisler RB, Han C, Burman WJ, Tedaldi EM, Neaton JD. Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr 2003; 34:379-386.
6. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy. Nat Med 2000; 6:82-85.
7. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
8. Olsen CH, Gatell J, Ledergerber B, Katlama C, Friis-Moller N, Weber J, et al. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen. AIDS 2005; 19:319-330.
9. Baker JV, Peng G, Rapkin J, Abrams DI, Silverberg MJ, Macarthur RD, et al. CD4Rcount and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22:841-848.
10. Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirk O, de WS, et al. Is there evidence for an increase in the death rate from liverrelated disease in patients with HIV? AIDS 2005; 19:2117- 2125.
11. Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22:2143-2153.
12. Reekie J, Kosa C, Engsig F, Monforte AD, Wiercinska-Drapalo A, Domingo P, et al. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome- defining malignancies. Cancer 2010; 116:5306-5315.
13. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the 'Mortalite 2000 and 2005' SURVEYS (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48:590-598.
14. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16:1663-1671.
15. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio MA, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
16. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41(RR- 17):1-19.
17. Kowalska JD, Mocroft A, Ledergerber B, Florence E, Ristola M, Begovac J, et al. A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non- AIDS related: results from the EuroSIDA study. HIV Clin Trials 2011; 12:109-117.
18. Kowalska JD, Friis-Moller N, Kirk O, Bannister W, Mocroft A, Sabin C, et al. The coding causes of death in HIV (CoDe) project: initial results and evaluation of methodology. Epidemiology 2011; 22:516-523.
19. Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 2010; 55:262- 270.
20. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387- 1396.
21. Daniels MJ, Hughes MD. Meta-analysis for the evaluation of potential surrogate markers. Stat Med 1997; 16:1965- 1982.
22. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125:605- 613.
23. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virusinfected patients: A case-control study nested within the French Hospital Database on HIV ANRS Cohort CO4. Arch Intern Med 2010; 170:1228-1238.
24. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multicohort collaboration. Lancet 2008; 371:1417-1426.
25. Baum PD, Sullam PM, Stoddart CA, McCune JM. Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. AIDS 2011; 25:2243-2248.
26. Palella FJ Jr, Phair JP. Cardiovascular disease in HIV infection. Curr Opin HIV AIDS 2011; 6:266-271.
27. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-1430.
28. Jones R, Sawleshwarkar S, Michailidis C, Jackson A, Mandalia S, Stebbing J, et al. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med 2005; 6:396-402.
29. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13:1659-1667.
30. Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis 2011; 53:84-91.
31. Regazzi M, Villani P, Gulminetti R, Cusato M, Brandolini M, Tinelli C, et al. Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens. Ther Drug Monit 2011; 33:303-308.
32. Ghosn J, Carosi G, Moreno S, Pokrovsky V, Lazzarin A, Pialoux G, et al. Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir- boosted regimen. Antivir Ther 2010; 15:993-1002.
33. Squires KE, Young B, Dejesus E, Bellos N, Murphy D, Zhao HH, et al. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavirboosted atazanavir in HIV-infected patients. AIDS 2010; 24:2019-2027.
34. Soliman EZ, Prineas RJ, Roediger MP, Duprez DA, Boccara F, Boesecke C, et al. Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study. J Electrocardiol 2011; 44:779-785.
35. Sension M, Andrade Neto JL, Grinsztejn B, Molina JM, Zavala I, Gonzalez-Garcia J, et al. Improvement in lipid profiles in antiretroviral- experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. J Acquir Immune Defic Syndr 2009; 51:153-162.